[symbol: see text]Quinupristin + dalfopristin for infections.
Quinupristin + dalfopristin* (Synercid -- Aventis Pharma Ltd) is a new combination antibacterial product licensed for treating patients with a variety of Gram-positive infections. Here we assess its place in clinical practice.
D000900:Anti-Bacterial Agents / Q000191:economics / Q000627:therapeutic use*; D016527:Drug Costs; D024881:Drug Resistance, Bacterial; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy* / Q000191:economics; D006801:Humans; D015163:Superinfection / Q000191:economics; D014769:Virginiamycin / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D014769:Virginiamycin; C113825:quinupristin; C113826:dalfopristin